Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 12/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.36 |
| ▸ | INCENP | Q9NQS7 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.33 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1224612 | 0.84 | SYK (0.51) | SYKAURKBINCENPFFAR1EGFR | |
| SCHEMBL15474677 | 0.78 | SYK (0.51) | SYKAURKBINCENPFFAR1EGFR | |
| SCHEMBL1225065 | 0.76 | SYK (0.42) | SYKAURKBINCENPALDH1A1TRPM5 | |
| SCHEMBL1224868 | 0.75 | LMNA (0.50) | ALDH1A1 | |
| SCHEMBL26136200 | 0.75 | GAA (0.51) | SYKALDH1A1TRPM5EGFRERBB2 | |
| SCHEMBL30354819 | 0.75 | GAA (0.51) | SYKALDH1A1TRPM5EGFRERBB2 | |
| SCHEMBL7208861 | 0.74 | KCNH2 (0.42) | ALDH1A1GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL1224802 | 0.74 | PLK1 (0.47) | ALDH1A1ERBB2 | |
| SCHEMBL339374 | 0.73 | HTR1A (0.53) | — | |
| SCHEMBL1225050 | 0.72 | FDPS (0.57) | ALDH1A1TRPM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010132615-A1 | HYDRAZONE COMPOUNDS AND THEIR USE | STEIN PHILIP (US) | 2010-11-18 | — | — | WO | claimed |
| US-20110033393-A1 | Hydrazone Compounds and Their Use | REDPOINT BIO CORPORATION | 2011-02-10 | — | — | US | disclosed |
| WO-2010132615-A1 | HYDRAZONE COMPOUNDS AND THEIR USE | STEIN PHILIP (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110033393-A1 | Hydrazone Compounds and Their Use | TRPM5, TRPV5, TRPM8 | SYK 4246/4885AURKB 3370/4885INCENP 4365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.